Fluvoxamine TOGETHER trial paper:
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
October 27, 2021
Gilmar Reis, PhD
Eduardo Augusto dos Santos Moreira-Silva, PhD
Daniela Carla Medeiros Silva, PhD
Prof Lehana Thabane, PhD
Aline Cruz Milagres, RN
Thiago Santiago Ferreira, MD
Castilho Vitor Quirino dos Santos
Vitoria Helena de Souza Campos
Ana Maria Ribeiro Nogueira, MD
Ana Paula Figueiredo Guimaraes de Almeida, MD
Eduardo Diniz Callegari, MD
Adhemar Dias de Figueiredo Neto, PhD
Leonardo Cançado Monteiro Savassi, PhD
Maria Izabel Campos Simplicio, BScPharm
Luciene Barra Ribeiro, RN
Rosemary Oliveira
Ofir Harari, PhD
Jamie I Forrest, MPH
Hinda Ruton, MSc
Sheila Sprague, PhD
Paula McKay, MSc
Alla V Glushchenko, MD
Craig R Rayner, FRCPE
Prof Eric J Lenze, MD
Angela M Reiersen, MD
Prof Gordon H Guyatt, MD
Prof Edward J Mills, FRCP
for the TOGETHER investigators
Here is an account of the early history of how Fluvoxamine became a drug candidate for covid19.
Summarizing the history presented in this CBS news story (which interviewed Steve Kirsch also):
https://www.cbsnews.com/news/fluvoxamine-antidepressant-drug-covid-treatment-60-minutes-2021-03-07/
Finding a possible early treatment for COVID-19 in a 40-year-old antidepressant
Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19.
Mar 7, 2021
Sharyn Alfonsi
The current interest in Fluvoxamine emerged from Psychiatrist Dr Angela Reiersen - inspired by a study of Fluvoxamine in mice - where it stopped sepsis (inflammatory).
Articles mentioning Dr Angela M. Reiersen:
https://online.flippingbook.com/view/329200553/9/
Follow Your Instincts
by Angela M. Reiersen, MD
https://insidemedicine.bulletin.com/399057735019874/?source=share_cta
Fluvoxamine: an inexpensive pill that works against Covid-19.Many existing drugs have been proposed for Covid-19. This one actually appears to work.
Jeremy Faust
28 Oct, 2021
Dr. Angela Reiersen contacted Dr. Eric Lenze (specialist in drug repurposing) about using Fluvoxamine:
Dr. Angela Reiersen
Dr. Eric Lenze
They started a trial with initial $20,000 funding from Univ. of Washington.
Ran out of funds - and got $67,000 funding from COVID Early Treatment Fund (Steve Kirsch)
- Steve Kirsch (inventor of the optical mouse and serial entrepreneur)
The trial completed in August 2020.
Trial on 152 people - 80 received Fluvoxamine (zero deteriorated) - vs 8% of placebo deteriorated.
Published in JAMA in November 2020.
Crickets.
Steve Kirsch mentioned Fluvoxamine in a webinar for Harvard Business School alumni - where Dr. David Seftel was listening.
Soon after Dr David Seftel heard about he outbreak of covid19 at Golden Gate Fields racetrack where he was medical director.
Dr David Seftel studied the JAMA paper and felt confident to use Fluvoxamine - 15 day course to the racetrack workers who had covid19.
Steve Kirsch added another $1M to fund a larger trial for Fluvoxamine led by Dr. Eric Lenze.
Link to Dr Eric Lenze's newer expanded trial using fluvoxamine:
https://stopcovidtrial.wustl.edu/
STOP COVID Trial
Fluvoxamine has shown very good results from the first trials.
They could not get NIH to fund these studies - as was the case with Ivermectin.
Steve Kirsch had to step in to fund some of the trials for Fluvoxamine.
He also promoted early treatments and is a supporter of Ivermectin.
TOGETHER trial - Fluvoxamine vs Ivermectin trials
For Fluvoxamine in the TOGETHER trial, there were academics involved who were interested in Fluvoxamine.
The TOGETHER ivermectin trial did not have advocates pushing for right dosing and duration:
TOGETHER administrators expressed hostility to the idea that Ivermectin could work
refused to entertain suggestions to use Ivermectin with fatty meal (and NOT on empty stomach - as that would reduce bioavailability by 2.5x)
refused to expand Ivermectin use beyond 3 days (currently Ivermectin is used for 5 days or more typically by clinicians)
The TOGETHER trial for Fluvoxamine showed good results - but perhaps could have been better still.
https://twitter.com/Covid19Crusher/status/1425564583637422086
It is interesting to note how much weaker the Fluvoxamine results are in the @TogetherTrial compared to the previous studies.
That might reflect a difference in the timeliness of the intervention, or nastiness of the variant, or specificity of the population treated, etc...
Even if NIH/CDC/WHO do not favor ivermectin - it remains to be seen if they are against Fluvoxamine and early treatment in general - will they advocate for Fluvoxamine use - as they did for the only marginal Remdesivir?
Dr Farid Jalai has been advocating for use of Cyproheptadine (starting near day7-8) and Fluvoxamine (starting early) - to prevent appearance of serotonin syndrome (platelets releasing serotonin leading to clotting).
This is described in:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3800402
COVID-19 Pathophysiology: Are Platelets and Serotonin Hiding in Plain Sight?
18 Mar 2021
Farid Jalali
Saddleback Medical Group
Salim Rezaie
CIUSSS EMTL
Philippe Rola
Greater San Antonio Emergency Physicians (GSEP)
Cameron Kyle-Sidell
Maimonides Medical Center - Department of Emergency Medicine
Date Written: February 5, 2021
However, as has happened with pre-prints on other generic drugs, the authors have had difficulty getting it published:
https://twitter.com/cameronks/status/1453820632488153088
Cameron Kyle-Sidell, MD
Please consider the following paper entitled “COVID-19 Pathophysiology: Are Platelets and Serotonin Hiding in Plain Sight?” We haven’t been able to get it published anywhere. Any suggestions are appreciated.
https://twitter.com/AngelaReiersen/status/1453847215638777862
Angela Reiersen, MD, MPE
I have read this paper. I think some or all of these ideas about platelets & serotonin in COVID19 might be correct. I will think some more about which journals might have interest in publishing this or a similar paper.
However, Fluvoxamine seems to have action beyond just for preventing serotonin syndrome - as it seems to help with long haulers and for brain fog etc also (see below).
The presumed mode of action for this seems to be it's action as a sigma 1 agonist:
https://www.frontiersin.org/articles/10.3389/fphar.2021.652688/full
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Vikas P. Sukhatme, Angela M. Reiersen, Sharat J. Vayttaden and Vidula V. Sukhatme
20 April 2021
Because of his advocacy, Fluvoxamine and Cyproheptadine have now been in the FLCCC MATH+ protocol for many months.
Dr Farid Jalali is also credited in the acknowledgements section of the paper above on mode of action of Fluvoxamine by Dr. Angela Reiersen and Dr. Eric Lenze.
Dr Syed Haider (drsyedhaider.com) and Dr Miguel Antonatos (Text2MD.com) - both telemedicine doctors doing early treatment - were early users of Fluvoxamine - and most of these doctors were in contact with Steve Kirsch, Dr Bruce Patterson, Dr Yo (covidlonghaulers.com) and sharing their experiences.
Feedback from these early treatment doctors further informed dosing and promotion efforts by Steve Kirsch for Fluvoxamine (he is also a supporter of ivermectin).
The experiences of the early treatment doctors - also exposed the benefit that Fluvoxamine offered for long haulers syndrome - notably against brain fog (conditions that may be better tackled by Fluvoxamine - which can cross the blood-brain barrier - which Ivermectin cannot).
The early treatment doctors have provided important feedback on real world issues to consider in practically
prescribing Fluvoxamine. Dr Syed Haider has appeared twice on Dr Been, and Dr Miguel Antonatos has appeared once.
Fluvoxamine crosses the blood-brain barrier (unlike ivermectin) - and all these doctors, including Dr Been have advocated for it's potential for reducing brain fog and such issues with long hauler syndrome.
And in practice Fluvoxamine has shown itself to be beneficial for long haulers as well, as well as for post-vax issues etc.
(continued below) ..
[–]stereomatch[S,M] [score hidden] stickied comment (0 children)
[–]spelllingchamp 2 insightful - 1 fun2 insightful - 0 fun3 insightful - 0 fun3 insightful - 1 fun - (3 children)
[–]stereomatch[S] 2 insightful - 1 fun2 insightful - 0 fun3 insightful - 0 fun3 insightful - 1 fun - (2 children)
[–]spelllingchamp 1 insightful - 1 fun1 insightful - 0 fun2 insightful - 0 fun2 insightful - 1 fun - (1 child)
[–]stereomatch[S] 1 insightful - 1 fun1 insightful - 0 fun2 insightful - 0 fun2 insightful - 1 fun - (0 children)